리서치사:Market Glass, Inc. (Formerly Global Industry Analysts, Inc.)
발행일:2024년 07월
페이지 정보:영문 208 Pages
라이선스 & 가격 (부가세 별도)
한글목차
임상시험 관리 시스템(CTMS)의 세계 시장은 2030년까지 45억 달러에 이를 전망
2023년에 17억 달러로 추정되는 임상시험 관리 시스템(CTMS) 세계 시장은 2030년에는 45억 달러에 이르고, 분석 기간 2023-2030년 CAGR은 14.5%로 성장할 것으로 예측됩니다. 이 보고서에서 분석한 부문 중 하나인 엔터프라이즈 와이드 CTMS는 CAGR 15.0%로 성장을 지속하고, 분석 기간이 끝날 때까지 31억 달러에 도달할 것으로 예측됩니다. 현장 CTMS 부문의 성장률은 분석 기간의 CAGR로 13.4%로 추정됩니다.
미국 시장은 4억 7,790만 달러, 중국은 CAGR 13.7%로 성장 예측
미국 임상시험 관리 시스템(CTMS) 시장은 2023년 4억 7,790만 달러로 추정됩니다. 세계 2위 경제대국인 중국은 2023년부터 2030년까지 13.7%의 연평균 복합 성장률(CAGR)로 성장하여 2030년에는 6억 8,490만 달러 규모에 이를 것으로 예측되고 있습니다. 다른 주목할만한 지역별 시장으로는 일본과 캐나다가 있으며, 각각 분석 기간 중에 12.6%와 12.0%의 연평균 복합 성장률(CAGR)로 성장할 것으로 예측되고 있습니다. 유럽에서는 독일이 CAGR 약 10.3%로 성장할 것으로 예측됩니다.
임상시험 관리 시스템(CTMS) - 주요 동향 및 촉진요인
임상시험 관리 시스템(CTMS)은 임상시험과 관련된 복잡하고 다면적인 프로세스를 원활하게 관리할 수 있는 현대의 임상연구에 필수적인 도구로 등장했습니다. CTMS 플랫폼은 임상시험 계획, 추적, 관리 등 다양한 기능을 통합하여 임상시험이 효율적으로 수행되고 규제 요건을 준수하며 높은 수준의 데이터 무결성을 유지할 수 있도록 합니다. 이러한 시스템은 시험 설정, 대상 등록, 방문 추적, 데이터 관리, 보고 등의 기능을 제공합니다. 이러한 기능을 중앙 집중화함으로써 CTMS는 시험의 진행 상황을 전반적으로 파악하고 이해 관계자간의 조정을 강화하고 관리 업무를 합리화하며 결국 임상 연구와 관련된 시간과 비용을 줄입니다. 이 종합적인 접근은 더 나은 의사 결정과 자원 배분을 촉진할뿐만 아니라 새로운 문제에 대한 신속한 대응 능력을 향상시킵니다.
CTMS의 도입은 기술의 진보와 임상시험의 복잡화에 의해 가속화되고 있습니다. 최신 CTMS 플랫폼은 인공지능, 머신러닝, 고급 분석 등의 첨단 기술을 활용하여 보다 고도로 예측적인 통찰력을 제공합니다. 예를 들어, AI가 탑재된 CTMS는 잠재적인 지연을 예측하고, 모집의 병목 현상을 파악하고, 최적의 자원 배분 전략을 제안할 수 있습니다. 또한 CTMS와 전자 의료 기록(EHR) 및 기타 의료 IT 시스템과의 통합을 통해 실시간 데이터 공유 및 임상시험 데이터의 정확성과 무결성을 향상시킬 수 있어 유용성이 더욱 확대됩니다. 이러한 통합은 일관된 데이터 수집 및 관리가 중요한 다중 시설 임상시험에서 특히 유용합니다. 분산형 임상시험(DCT)의 동향도 CTMS의 중요성을 돋보이게 합니다. CTMS는 원격 모니터링과 관리를 용이하게 하고 다양한 임상시험시설 시설 간의 연속성과 컴플라이언스를 보장하기 때문입니다.
임상시험관리시스템 시장의 성장은 몇 가지 요인에 의해 야기됩니다. 만성 질환의 유병률 증가와 새로운 치료법의 긴급한 필요성에 힘입어 임상시험 수가 증가함에 따라 효율적인 임상시험 관리 솔루션에 대한 수요가 증가하고 있습니다. 제약 및 생명공학 산업은 R&D에 엄청난 투자를 하고 있으며, 첨단 CTMS 플랫폼의 필요성을 더욱 강화하고 있습니다. CTMS는 엄격한 문서화 및 보고 기준을 유지하는 데 도움이 되므로 규제 요건과 GCP(의약품 임상시험 실시 기준) 및 ICH(국제의약품평가조화위원회) 가이드라인 등 기준 준수의 필요성 심지어 중요한 촉진요인이되었습니다. 또한 환자 중심의 임상시험과 맞춤형 의료로의 전환이 다양하고 역동적인 시험 설계에 대응할 수 있는 보다 적응성이 높고 유연한 CTMS 솔루션에 대한 수요를 끌어올리고 있습니다. 클라우드 기반 CTMS의 채택이 확대되고 있는 것도 중요한 요인이며, 확장성 향상, IT 비용 절감, 접근성 향상이 실현되고 있습니다. 이러한 촉진요인은 임상시험 과정을 최적화하고 규제 규정 준수를 보장하며 궁극적으로 새로운 치료법 시장 진입을 가속화하는 데 CTMS가 필수적인 역할을 한다는 것을 뒷받침합니다.
조사 대상 기업 예(주목 71사)
ArisGlobal LLC
BioClinica Inc.
Bio-Optronics Inc.
DSG Inc.
eResearch Technology Inc.
IBM Watson Health
Medidata Solutions
MedNet Solutions
Nextrials Inc.
Oracle Corp.
PAREXEL International Corp.
Trial By Fire Solutions LLC
Veeva Systems Inc.
목차
제1장 조사 방법
제2장 주요 요약
시장 개요
주요 기업
시장 동향과 촉진요인
세계 시장 전망
제3장 시장 분석
미국
캐나다
일본
중국
유럽
프랑스
독일
이탈리아
영국
기타 유럽
아시아태평양
세계 기타 지역
제4장 경쟁
JHS
영문 목차
영문목차
Global Clinical Trial Management Systems (CTMS) Market to Reach US$4.5 Billion by 2030
The global market for Clinical Trial Management Systems (CTMS) estimated at US$1.7 Billion in the year 2023, is expected to reach US$4.5 Billion by 2030, growing at a CAGR of 14.5% over the analysis period 2023-2030. Enterprise-Wide CTMS, one of the segments analyzed in the report, is expected to record a 15.0% CAGR and reach US$3.1 Billion by the end of the analysis period. Growth in the On-Site CTMS segment is estimated at 13.4% CAGR over the analysis period.
The U.S. Market is Estimated at US$477.9 Million While China is Forecast to Grow at 13.7% CAGR
The Clinical Trial Management Systems (CTMS) market in the U.S. is estimated at US$477.9 Million in the year 2023. China, the world's second largest economy, is forecast to reach a projected market size of US$684.9 Million by the year 2030 trailing a CAGR of 13.7% over the analysis period 2023-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 12.6% and 12.0% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 10.3% CAGR.
Clinical Trial Management Systems (CTMS) - Key Trends and Drivers
Clinical Trial Management Systems (CTMS) have emerged as indispensable tools in the modern clinical research landscape, enabling seamless management of the complex, multifaceted processes involved in clinical trials. CTMS platforms integrate various functions such as trial planning, tracking, and management, ensuring that clinical trials are conducted efficiently, adhere to regulatory requirements, and maintain high standards of data integrity. These systems offer features like study setup, subject enrollment, visit tracking, data management, and reporting. By centralizing these functions, CTMS provides a holistic view of trial progress, enhances coordination among stakeholders, and streamlines administrative tasks, ultimately reducing the time and cost associated with clinical research. This comprehensive approach not only facilitates better decision-making and resource allocation but also enhances the ability to respond to emerging issues swiftly.
The adoption of CTMS has been accelerated by advancements in technology and the increasing complexity of clinical trials. Modern CTMS platforms are leveraging cutting-edge technologies such as artificial intelligence, machine learning, and advanced analytics to provide more sophisticated and predictive insights. For instance, AI-powered CTMS can predict potential delays, identify recruitment bottlenecks, and suggest optimal resource allocation strategies. Additionally, the integration of CTMS with electronic health records (EHR) and other healthcare IT systems has further expanded their utility, enabling real-time data sharing and improving the accuracy and completeness of clinical trial data. These integrations are particularly valuable in multi-center trials where consistent data collection and management are critical. The trend towards decentralized clinical trials (DCTs) has also highlighted the importance of CTMS, as these systems facilitate remote monitoring and management, ensuring continuity and compliance across various trial sites.
The growth in the Clinical Trial Management Systems market is driven by several factors. The increasing number of clinical trials, fueled by the rising prevalence of chronic diseases and the urgent need for new therapies, has created a robust demand for efficient trial management solutions. The pharmaceutical and biotechnology industries are heavily investing in research and development, further propelling the need for advanced CTMS platforms. Regulatory requirements and the need for compliance with standards such as Good Clinical Practice (GCP) and the International Council for Harmonisation (ICH) guidelines are also significant drivers, as CTMS helps in maintaining rigorous documentation and reporting standards. Additionally, the shift towards patient-centric trials and personalized medicine is pushing the demand for more adaptive and flexible CTMS solutions that can cater to diverse and dynamic trial designs. The growing adoption of cloud-based CTMS is another critical factor, offering enhanced scalability, reduced IT costs, and improved accessibility. These drivers collectively underscore the essential role of CTMS in optimizing clinical trial processes, ensuring regulatory compliance, and ultimately accelerating the delivery of new treatments to the market.
Select Competitors (Total 71 Featured) -
ArisGlobal LLC
BioClinica Inc.
Bio-Optronics Inc.
DSG Inc.
eResearch Technology Inc.
IBM Watson Health
Medidata Solutions
MedNet Solutions
Nextrials Inc.
Oracle Corp.
PAREXEL International Corp.
Trial By Fire Solutions LLC
Veeva Systems Inc.
TABLE OF CONTENTS
I. METHODOLOGY
II. EXECUTIVE SUMMARY
1. MARKET OVERVIEW
Influencer Market Insights
Global Economic Update
Clinical Trial Management Systems (CTMS) - Global Key Competitors Percentage Market Share in 2024 (E)
Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2024 (E)
2. FOCUS ON SELECT PLAYERS
3. MARKET TRENDS & DRIVERS
Digital Transformation in Healthcare Spurs Adoption of CTMS Solutions
Advances in Cloud Computing Expand Addressable Market Opportunity
Increased Clinical Trial Complexity Strengthens Business Case for CTMS
The Rise of Decentralized Trials Propels Growth of CTMS Market
Integration of AI and Machine Learning Technologies Generates New Opportunities for CTMS
Adoption of eClinical Solutions Drives Market Expansion
Focus on Patient-Centric Trials Accelerates Demand for CTMS
Growing Outsourcing of Clinical Trials to CROs Fuels CTMS Market Growth
Increased Investment in Life Sciences Sector Drives Adoption of CTMS
Interoperability Challenges and Solutions Generate Demand for CTMS
The Push for Real-World Evidence (RWE) Strengthens Business Case for CTMS
Rising Number of Clinical Trials Globally Expands Addressable Market Opportunity
Technological Innovations in CTMS Platforms Propel Market Growth
Growth in Biopharmaceutical and Medical Device R&D Generates Demand for CTMS
Efforts to Improve Trial Efficiency and Reduce Costs Drive CTMS Market
Adoption of Mobile and Remote Monitoring Technologies Spurs Demand for CTMS
4. GLOBAL MARKET PERSPECTIVE
TABLE 1: World Clinical Trial Management Systems (CTMS) Market Analysis of Annual Sales in US$ Thousand for Years 2014 through 2030
TABLE 2: World Recent Past, Current & Future Analysis for Clinical Trial Management Systems (CTMS) by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
TABLE 3: World Historic Review for Clinical Trial Management Systems (CTMS) by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
TABLE 4: World 16-Year Perspective for Clinical Trial Management Systems (CTMS) by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets for Years 2014, 2024 & 2030
TABLE 5: World Recent Past, Current & Future Analysis for Enterprise-Wide CTMS by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
TABLE 6: World Historic Review for Enterprise-Wide CTMS by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
TABLE 7: World 16-Year Perspective for Enterprise-Wide CTMS by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2024 & 2030
TABLE 8: World Recent Past, Current & Future Analysis for On-Site CTMS by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
TABLE 9: World Historic Review for On-Site CTMS by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
TABLE 10: World 16-Year Perspective for On-Site CTMS by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2024 & 2030
TABLE 11: World Recent Past, Current & Future Analysis for Web-Based (On-demand) by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
TABLE 12: World Historic Review for Web-Based (On-demand) by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
TABLE 13: World 16-Year Perspective for Web-Based (On-demand) by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2024 & 2030
TABLE 14: World Recent Past, Current & Future Analysis for Licensed Enterprise (On-Premise) by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
TABLE 15: World Historic Review for Licensed Enterprise (On-Premise) by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
TABLE 16: World 16-Year Perspective for Licensed Enterprise (On-Premise) by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2024 & 2030
TABLE 17: World Recent Past, Current & Future Analysis for Cloud (SaaS) by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
TABLE 18: World Historic Review for Cloud (SaaS) by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
TABLE 19: World 16-Year Perspective for Cloud (SaaS) by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2024 & 2030
TABLE 20: World Recent Past, Current & Future Analysis for Large Pharma-Biotech Companies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
TABLE 21: World Historic Review for Large Pharma-Biotech Companies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
TABLE 22: World 16-Year Perspective for Large Pharma-Biotech Companies by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2024 & 2030
TABLE 23: World Recent Past, Current & Future Analysis for CROs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
TABLE 24: World Historic Review for CROs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
TABLE 25: World 16-Year Perspective for CROs by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2024 & 2030
TABLE 26: World Recent Past, Current & Future Analysis for Medical Device Manufacturers by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
TABLE 27: World Historic Review for Medical Device Manufacturers by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
TABLE 28: World 16-Year Perspective for Medical Device Manufacturers by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2024 & 2030
TABLE 29: World Recent Past, Current & Future Analysis for Small & Mid-Sized Pharma-Biotech Companies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
TABLE 30: World Historic Review for Small & Mid-Sized Pharma-Biotech Companies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
TABLE 31: World 16-Year Perspective for Small & Mid-Sized Pharma-Biotech Companies by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2024 & 2030
TABLE 32: World Recent Past, Current & Future Analysis for Other End-Uses by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
TABLE 33: World Historic Review for Other End-Uses by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
TABLE 34: World 16-Year Perspective for Other End-Uses by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2024 & 2030
III. MARKET ANALYSIS
UNITED STATES
Clinical Trial Management Systems (CTMS) Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2024 (E)
TABLE 35: USA Recent Past, Current & Future Analysis for Clinical Trial Management Systems (CTMS) by Deployment - Enterprise-Wide CTMS and On-Site CTMS - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
TABLE 36: USA Historic Review for Clinical Trial Management Systems (CTMS) by Deployment - Enterprise-Wide CTMS and On-Site CTMS Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
TABLE 37: USA 16-Year Perspective for Clinical Trial Management Systems (CTMS) by Deployment - Percentage Breakdown of Value Sales for Enterprise-Wide CTMS and On-Site CTMS for the Years 2014, 2024 & 2030
TABLE 38: USA Recent Past, Current & Future Analysis for Clinical Trial Management Systems (CTMS) by Delivery mode - Web-Based (On-demand), Licensed Enterprise (On-Premise) and Cloud (SaaS) - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
TABLE 39: USA Historic Review for Clinical Trial Management Systems (CTMS) by Delivery mode - Web-Based (On-demand), Licensed Enterprise (On-Premise) and Cloud (SaaS) Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
TABLE 40: USA 16-Year Perspective for Clinical Trial Management Systems (CTMS) by Delivery mode - Percentage Breakdown of Value Sales for Web-Based (On-demand), Licensed Enterprise (On-Premise) and Cloud (SaaS) for the Years 2014, 2024 & 2030
TABLE 41: USA Recent Past, Current & Future Analysis for Clinical Trial Management Systems (CTMS) by End-Use - Large Pharma-Biotech Companies, CROs, Medical Device Manufacturers, Small & Mid-Sized Pharma-Biotech Companies and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
TABLE 42: USA Historic Review for Clinical Trial Management Systems (CTMS) by End-Use - Large Pharma-Biotech Companies, CROs, Medical Device Manufacturers, Small & Mid-Sized Pharma-Biotech Companies and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
TABLE 43: USA 16-Year Perspective for Clinical Trial Management Systems (CTMS) by End-Use - Percentage Breakdown of Value Sales for Large Pharma-Biotech Companies, CROs, Medical Device Manufacturers, Small & Mid-Sized Pharma-Biotech Companies and Other End-Uses for the Years 2014, 2024 & 2030
CANADA
TABLE 44: Canada Recent Past, Current & Future Analysis for Clinical Trial Management Systems (CTMS) by Deployment - Enterprise-Wide CTMS and On-Site CTMS - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
TABLE 45: Canada Historic Review for Clinical Trial Management Systems (CTMS) by Deployment - Enterprise-Wide CTMS and On-Site CTMS Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
TABLE 46: Canada 16-Year Perspective for Clinical Trial Management Systems (CTMS) by Deployment - Percentage Breakdown of Value Sales for Enterprise-Wide CTMS and On-Site CTMS for the Years 2014, 2024 & 2030
TABLE 47: Canada Recent Past, Current & Future Analysis for Clinical Trial Management Systems (CTMS) by Delivery mode - Web-Based (On-demand), Licensed Enterprise (On-Premise) and Cloud (SaaS) - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
TABLE 48: Canada Historic Review for Clinical Trial Management Systems (CTMS) by Delivery mode - Web-Based (On-demand), Licensed Enterprise (On-Premise) and Cloud (SaaS) Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
TABLE 49: Canada 16-Year Perspective for Clinical Trial Management Systems (CTMS) by Delivery mode - Percentage Breakdown of Value Sales for Web-Based (On-demand), Licensed Enterprise (On-Premise) and Cloud (SaaS) for the Years 2014, 2024 & 2030
TABLE 50: Canada Recent Past, Current & Future Analysis for Clinical Trial Management Systems (CTMS) by End-Use - Large Pharma-Biotech Companies, CROs, Medical Device Manufacturers, Small & Mid-Sized Pharma-Biotech Companies and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
TABLE 51: Canada Historic Review for Clinical Trial Management Systems (CTMS) by End-Use - Large Pharma-Biotech Companies, CROs, Medical Device Manufacturers, Small & Mid-Sized Pharma-Biotech Companies and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
TABLE 52: Canada 16-Year Perspective for Clinical Trial Management Systems (CTMS) by End-Use - Percentage Breakdown of Value Sales for Large Pharma-Biotech Companies, CROs, Medical Device Manufacturers, Small & Mid-Sized Pharma-Biotech Companies and Other End-Uses for the Years 2014, 2024 & 2030
JAPAN
Clinical Trial Management Systems (CTMS) Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2024 (E)
TABLE 53: Japan Recent Past, Current & Future Analysis for Clinical Trial Management Systems (CTMS) by Deployment - Enterprise-Wide CTMS and On-Site CTMS - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
TABLE 54: Japan Historic Review for Clinical Trial Management Systems (CTMS) by Deployment - Enterprise-Wide CTMS and On-Site CTMS Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
TABLE 55: Japan 16-Year Perspective for Clinical Trial Management Systems (CTMS) by Deployment - Percentage Breakdown of Value Sales for Enterprise-Wide CTMS and On-Site CTMS for the Years 2014, 2024 & 2030
TABLE 56: Japan Recent Past, Current & Future Analysis for Clinical Trial Management Systems (CTMS) by Delivery mode - Web-Based (On-demand), Licensed Enterprise (On-Premise) and Cloud (SaaS) - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
TABLE 57: Japan Historic Review for Clinical Trial Management Systems (CTMS) by Delivery mode - Web-Based (On-demand), Licensed Enterprise (On-Premise) and Cloud (SaaS) Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
TABLE 58: Japan 16-Year Perspective for Clinical Trial Management Systems (CTMS) by Delivery mode - Percentage Breakdown of Value Sales for Web-Based (On-demand), Licensed Enterprise (On-Premise) and Cloud (SaaS) for the Years 2014, 2024 & 2030
TABLE 59: Japan Recent Past, Current & Future Analysis for Clinical Trial Management Systems (CTMS) by End-Use - Large Pharma-Biotech Companies, CROs, Medical Device Manufacturers, Small & Mid-Sized Pharma-Biotech Companies and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
TABLE 60: Japan Historic Review for Clinical Trial Management Systems (CTMS) by End-Use - Large Pharma-Biotech Companies, CROs, Medical Device Manufacturers, Small & Mid-Sized Pharma-Biotech Companies and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
TABLE 61: Japan 16-Year Perspective for Clinical Trial Management Systems (CTMS) by End-Use - Percentage Breakdown of Value Sales for Large Pharma-Biotech Companies, CROs, Medical Device Manufacturers, Small & Mid-Sized Pharma-Biotech Companies and Other End-Uses for the Years 2014, 2024 & 2030
CHINA
Clinical Trial Management Systems (CTMS) Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2024 (E)
TABLE 62: China Recent Past, Current & Future Analysis for Clinical Trial Management Systems (CTMS) by Deployment - Enterprise-Wide CTMS and On-Site CTMS - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
TABLE 63: China Historic Review for Clinical Trial Management Systems (CTMS) by Deployment - Enterprise-Wide CTMS and On-Site CTMS Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
TABLE 64: China 16-Year Perspective for Clinical Trial Management Systems (CTMS) by Deployment - Percentage Breakdown of Value Sales for Enterprise-Wide CTMS and On-Site CTMS for the Years 2014, 2024 & 2030
TABLE 65: China Recent Past, Current & Future Analysis for Clinical Trial Management Systems (CTMS) by Delivery mode - Web-Based (On-demand), Licensed Enterprise (On-Premise) and Cloud (SaaS) - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
TABLE 66: China Historic Review for Clinical Trial Management Systems (CTMS) by Delivery mode - Web-Based (On-demand), Licensed Enterprise (On-Premise) and Cloud (SaaS) Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
TABLE 67: China 16-Year Perspective for Clinical Trial Management Systems (CTMS) by Delivery mode - Percentage Breakdown of Value Sales for Web-Based (On-demand), Licensed Enterprise (On-Premise) and Cloud (SaaS) for the Years 2014, 2024 & 2030
TABLE 68: China Recent Past, Current & Future Analysis for Clinical Trial Management Systems (CTMS) by End-Use - Large Pharma-Biotech Companies, CROs, Medical Device Manufacturers, Small & Mid-Sized Pharma-Biotech Companies and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
TABLE 69: China Historic Review for Clinical Trial Management Systems (CTMS) by End-Use - Large Pharma-Biotech Companies, CROs, Medical Device Manufacturers, Small & Mid-Sized Pharma-Biotech Companies and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
TABLE 70: China 16-Year Perspective for Clinical Trial Management Systems (CTMS) by End-Use - Percentage Breakdown of Value Sales for Large Pharma-Biotech Companies, CROs, Medical Device Manufacturers, Small & Mid-Sized Pharma-Biotech Companies and Other End-Uses for the Years 2014, 2024 & 2030
EUROPE
Clinical Trial Management Systems (CTMS) Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2024 (E)
TABLE 71: Europe Recent Past, Current & Future Analysis for Clinical Trial Management Systems (CTMS) by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
TABLE 72: Europe Historic Review for Clinical Trial Management Systems (CTMS) by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
TABLE 73: Europe 16-Year Perspective for Clinical Trial Management Systems (CTMS) by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK and Rest of Europe Markets for Years 2014, 2024 & 2030
TABLE 74: Europe Recent Past, Current & Future Analysis for Clinical Trial Management Systems (CTMS) by Deployment - Enterprise-Wide CTMS and On-Site CTMS - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
TABLE 75: Europe Historic Review for Clinical Trial Management Systems (CTMS) by Deployment - Enterprise-Wide CTMS and On-Site CTMS Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
TABLE 76: Europe 16-Year Perspective for Clinical Trial Management Systems (CTMS) by Deployment - Percentage Breakdown of Value Sales for Enterprise-Wide CTMS and On-Site CTMS for the Years 2014, 2024 & 2030
TABLE 77: Europe Recent Past, Current & Future Analysis for Clinical Trial Management Systems (CTMS) by Delivery mode - Web-Based (On-demand), Licensed Enterprise (On-Premise) and Cloud (SaaS) - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
TABLE 78: Europe Historic Review for Clinical Trial Management Systems (CTMS) by Delivery mode - Web-Based (On-demand), Licensed Enterprise (On-Premise) and Cloud (SaaS) Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
TABLE 79: Europe 16-Year Perspective for Clinical Trial Management Systems (CTMS) by Delivery mode - Percentage Breakdown of Value Sales for Web-Based (On-demand), Licensed Enterprise (On-Premise) and Cloud (SaaS) for the Years 2014, 2024 & 2030
TABLE 80: Europe Recent Past, Current & Future Analysis for Clinical Trial Management Systems (CTMS) by End-Use - Large Pharma-Biotech Companies, CROs, Medical Device Manufacturers, Small & Mid-Sized Pharma-Biotech Companies and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
TABLE 81: Europe Historic Review for Clinical Trial Management Systems (CTMS) by End-Use - Large Pharma-Biotech Companies, CROs, Medical Device Manufacturers, Small & Mid-Sized Pharma-Biotech Companies and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
TABLE 82: Europe 16-Year Perspective for Clinical Trial Management Systems (CTMS) by End-Use - Percentage Breakdown of Value Sales for Large Pharma-Biotech Companies, CROs, Medical Device Manufacturers, Small & Mid-Sized Pharma-Biotech Companies and Other End-Uses for the Years 2014, 2024 & 2030
FRANCE
Clinical Trial Management Systems (CTMS) Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2024 (E)
TABLE 83: France Recent Past, Current & Future Analysis for Clinical Trial Management Systems (CTMS) by Deployment - Enterprise-Wide CTMS and On-Site CTMS - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
TABLE 84: France Historic Review for Clinical Trial Management Systems (CTMS) by Deployment - Enterprise-Wide CTMS and On-Site CTMS Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
TABLE 85: France 16-Year Perspective for Clinical Trial Management Systems (CTMS) by Deployment - Percentage Breakdown of Value Sales for Enterprise-Wide CTMS and On-Site CTMS for the Years 2014, 2024 & 2030
TABLE 86: France Recent Past, Current & Future Analysis for Clinical Trial Management Systems (CTMS) by Delivery mode - Web-Based (On-demand), Licensed Enterprise (On-Premise) and Cloud (SaaS) - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
TABLE 87: France Historic Review for Clinical Trial Management Systems (CTMS) by Delivery mode - Web-Based (On-demand), Licensed Enterprise (On-Premise) and Cloud (SaaS) Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
TABLE 88: France 16-Year Perspective for Clinical Trial Management Systems (CTMS) by Delivery mode - Percentage Breakdown of Value Sales for Web-Based (On-demand), Licensed Enterprise (On-Premise) and Cloud (SaaS) for the Years 2014, 2024 & 2030
TABLE 89: France Recent Past, Current & Future Analysis for Clinical Trial Management Systems (CTMS) by End-Use - Large Pharma-Biotech Companies, CROs, Medical Device Manufacturers, Small & Mid-Sized Pharma-Biotech Companies and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
TABLE 90: France Historic Review for Clinical Trial Management Systems (CTMS) by End-Use - Large Pharma-Biotech Companies, CROs, Medical Device Manufacturers, Small & Mid-Sized Pharma-Biotech Companies and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
TABLE 91: France 16-Year Perspective for Clinical Trial Management Systems (CTMS) by End-Use - Percentage Breakdown of Value Sales for Large Pharma-Biotech Companies, CROs, Medical Device Manufacturers, Small & Mid-Sized Pharma-Biotech Companies and Other End-Uses for the Years 2014, 2024 & 2030
GERMANY
Clinical Trial Management Systems (CTMS) Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2024 (E)
TABLE 92: Germany Recent Past, Current & Future Analysis for Clinical Trial Management Systems (CTMS) by Deployment - Enterprise-Wide CTMS and On-Site CTMS - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
TABLE 93: Germany Historic Review for Clinical Trial Management Systems (CTMS) by Deployment - Enterprise-Wide CTMS and On-Site CTMS Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
TABLE 94: Germany 16-Year Perspective for Clinical Trial Management Systems (CTMS) by Deployment - Percentage Breakdown of Value Sales for Enterprise-Wide CTMS and On-Site CTMS for the Years 2014, 2024 & 2030
TABLE 95: Germany Recent Past, Current & Future Analysis for Clinical Trial Management Systems (CTMS) by Delivery mode - Web-Based (On-demand), Licensed Enterprise (On-Premise) and Cloud (SaaS) - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
TABLE 96: Germany Historic Review for Clinical Trial Management Systems (CTMS) by Delivery mode - Web-Based (On-demand), Licensed Enterprise (On-Premise) and Cloud (SaaS) Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
TABLE 97: Germany 16-Year Perspective for Clinical Trial Management Systems (CTMS) by Delivery mode - Percentage Breakdown of Value Sales for Web-Based (On-demand), Licensed Enterprise (On-Premise) and Cloud (SaaS) for the Years 2014, 2024 & 2030
TABLE 98: Germany Recent Past, Current & Future Analysis for Clinical Trial Management Systems (CTMS) by End-Use - Large Pharma-Biotech Companies, CROs, Medical Device Manufacturers, Small & Mid-Sized Pharma-Biotech Companies and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
TABLE 99: Germany Historic Review for Clinical Trial Management Systems (CTMS) by End-Use - Large Pharma-Biotech Companies, CROs, Medical Device Manufacturers, Small & Mid-Sized Pharma-Biotech Companies and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
TABLE 100: Germany 16-Year Perspective for Clinical Trial Management Systems (CTMS) by End-Use - Percentage Breakdown of Value Sales for Large Pharma-Biotech Companies, CROs, Medical Device Manufacturers, Small & Mid-Sized Pharma-Biotech Companies and Other End-Uses for the Years 2014, 2024 & 2030
ITALY
TABLE 101: Italy Recent Past, Current & Future Analysis for Clinical Trial Management Systems (CTMS) by Deployment - Enterprise-Wide CTMS and On-Site CTMS - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
TABLE 102: Italy Historic Review for Clinical Trial Management Systems (CTMS) by Deployment - Enterprise-Wide CTMS and On-Site CTMS Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
TABLE 103: Italy 16-Year Perspective for Clinical Trial Management Systems (CTMS) by Deployment - Percentage Breakdown of Value Sales for Enterprise-Wide CTMS and On-Site CTMS for the Years 2014, 2024 & 2030
TABLE 104: Italy Recent Past, Current & Future Analysis for Clinical Trial Management Systems (CTMS) by Delivery mode - Web-Based (On-demand), Licensed Enterprise (On-Premise) and Cloud (SaaS) - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
TABLE 105: Italy Historic Review for Clinical Trial Management Systems (CTMS) by Delivery mode - Web-Based (On-demand), Licensed Enterprise (On-Premise) and Cloud (SaaS) Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
TABLE 106: Italy 16-Year Perspective for Clinical Trial Management Systems (CTMS) by Delivery mode - Percentage Breakdown of Value Sales for Web-Based (On-demand), Licensed Enterprise (On-Premise) and Cloud (SaaS) for the Years 2014, 2024 & 2030
TABLE 107: Italy Recent Past, Current & Future Analysis for Clinical Trial Management Systems (CTMS) by End-Use - Large Pharma-Biotech Companies, CROs, Medical Device Manufacturers, Small & Mid-Sized Pharma-Biotech Companies and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
TABLE 108: Italy Historic Review for Clinical Trial Management Systems (CTMS) by End-Use - Large Pharma-Biotech Companies, CROs, Medical Device Manufacturers, Small & Mid-Sized Pharma-Biotech Companies and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
TABLE 109: Italy 16-Year Perspective for Clinical Trial Management Systems (CTMS) by End-Use - Percentage Breakdown of Value Sales for Large Pharma-Biotech Companies, CROs, Medical Device Manufacturers, Small & Mid-Sized Pharma-Biotech Companies and Other End-Uses for the Years 2014, 2024 & 2030
UNITED KINGDOM
Clinical Trial Management Systems (CTMS) Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2024 (E)
TABLE 110: UK Recent Past, Current & Future Analysis for Clinical Trial Management Systems (CTMS) by Deployment - Enterprise-Wide CTMS and On-Site CTMS - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
TABLE 111: UK Historic Review for Clinical Trial Management Systems (CTMS) by Deployment - Enterprise-Wide CTMS and On-Site CTMS Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
TABLE 112: UK 16-Year Perspective for Clinical Trial Management Systems (CTMS) by Deployment - Percentage Breakdown of Value Sales for Enterprise-Wide CTMS and On-Site CTMS for the Years 2014, 2024 & 2030
TABLE 113: UK Recent Past, Current & Future Analysis for Clinical Trial Management Systems (CTMS) by Delivery mode - Web-Based (On-demand), Licensed Enterprise (On-Premise) and Cloud (SaaS) - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
TABLE 114: UK Historic Review for Clinical Trial Management Systems (CTMS) by Delivery mode - Web-Based (On-demand), Licensed Enterprise (On-Premise) and Cloud (SaaS) Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
TABLE 115: UK 16-Year Perspective for Clinical Trial Management Systems (CTMS) by Delivery mode - Percentage Breakdown of Value Sales for Web-Based (On-demand), Licensed Enterprise (On-Premise) and Cloud (SaaS) for the Years 2014, 2024 & 2030
TABLE 116: UK Recent Past, Current & Future Analysis for Clinical Trial Management Systems (CTMS) by End-Use - Large Pharma-Biotech Companies, CROs, Medical Device Manufacturers, Small & Mid-Sized Pharma-Biotech Companies and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
TABLE 117: UK Historic Review for Clinical Trial Management Systems (CTMS) by End-Use - Large Pharma-Biotech Companies, CROs, Medical Device Manufacturers, Small & Mid-Sized Pharma-Biotech Companies and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
TABLE 118: UK 16-Year Perspective for Clinical Trial Management Systems (CTMS) by End-Use - Percentage Breakdown of Value Sales for Large Pharma-Biotech Companies, CROs, Medical Device Manufacturers, Small & Mid-Sized Pharma-Biotech Companies and Other End-Uses for the Years 2014, 2024 & 2030
REST OF EUROPE
TABLE 119: Rest of Europe Recent Past, Current & Future Analysis for Clinical Trial Management Systems (CTMS) by Deployment - Enterprise-Wide CTMS and On-Site CTMS - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
TABLE 120: Rest of Europe Historic Review for Clinical Trial Management Systems (CTMS) by Deployment - Enterprise-Wide CTMS and On-Site CTMS Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
TABLE 121: Rest of Europe 16-Year Perspective for Clinical Trial Management Systems (CTMS) by Deployment - Percentage Breakdown of Value Sales for Enterprise-Wide CTMS and On-Site CTMS for the Years 2014, 2024 & 2030
TABLE 122: Rest of Europe Recent Past, Current & Future Analysis for Clinical Trial Management Systems (CTMS) by Delivery mode - Web-Based (On-demand), Licensed Enterprise (On-Premise) and Cloud (SaaS) - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
TABLE 123: Rest of Europe Historic Review for Clinical Trial Management Systems (CTMS) by Delivery mode - Web-Based (On-demand), Licensed Enterprise (On-Premise) and Cloud (SaaS) Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
TABLE 124: Rest of Europe 16-Year Perspective for Clinical Trial Management Systems (CTMS) by Delivery mode - Percentage Breakdown of Value Sales for Web-Based (On-demand), Licensed Enterprise (On-Premise) and Cloud (SaaS) for the Years 2014, 2024 & 2030
TABLE 125: Rest of Europe Recent Past, Current & Future Analysis for Clinical Trial Management Systems (CTMS) by End-Use - Large Pharma-Biotech Companies, CROs, Medical Device Manufacturers, Small & Mid-Sized Pharma-Biotech Companies and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
TABLE 126: Rest of Europe Historic Review for Clinical Trial Management Systems (CTMS) by End-Use - Large Pharma-Biotech Companies, CROs, Medical Device Manufacturers, Small & Mid-Sized Pharma-Biotech Companies and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
TABLE 127: Rest of Europe 16-Year Perspective for Clinical Trial Management Systems (CTMS) by End-Use - Percentage Breakdown of Value Sales for Large Pharma-Biotech Companies, CROs, Medical Device Manufacturers, Small & Mid-Sized Pharma-Biotech Companies and Other End-Uses for the Years 2014, 2024 & 2030
ASIA-PACIFIC
Clinical Trial Management Systems (CTMS) Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2024 (E)
TABLE 128: Asia-Pacific Recent Past, Current & Future Analysis for Clinical Trial Management Systems (CTMS) by Deployment - Enterprise-Wide CTMS and On-Site CTMS - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
TABLE 129: Asia-Pacific Historic Review for Clinical Trial Management Systems (CTMS) by Deployment - Enterprise-Wide CTMS and On-Site CTMS Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
TABLE 130: Asia-Pacific 16-Year Perspective for Clinical Trial Management Systems (CTMS) by Deployment - Percentage Breakdown of Value Sales for Enterprise-Wide CTMS and On-Site CTMS for the Years 2014, 2024 & 2030
TABLE 131: Asia-Pacific Recent Past, Current & Future Analysis for Clinical Trial Management Systems (CTMS) by Delivery mode - Web-Based (On-demand), Licensed Enterprise (On-Premise) and Cloud (SaaS) - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
TABLE 132: Asia-Pacific Historic Review for Clinical Trial Management Systems (CTMS) by Delivery mode - Web-Based (On-demand), Licensed Enterprise (On-Premise) and Cloud (SaaS) Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
TABLE 133: Asia-Pacific 16-Year Perspective for Clinical Trial Management Systems (CTMS) by Delivery mode - Percentage Breakdown of Value Sales for Web-Based (On-demand), Licensed Enterprise (On-Premise) and Cloud (SaaS) for the Years 2014, 2024 & 2030
TABLE 134: Asia-Pacific Recent Past, Current & Future Analysis for Clinical Trial Management Systems (CTMS) by End-Use - Large Pharma-Biotech Companies, CROs, Medical Device Manufacturers, Small & Mid-Sized Pharma-Biotech Companies and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
TABLE 135: Asia-Pacific Historic Review for Clinical Trial Management Systems (CTMS) by End-Use - Large Pharma-Biotech Companies, CROs, Medical Device Manufacturers, Small & Mid-Sized Pharma-Biotech Companies and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
TABLE 136: Asia-Pacific 16-Year Perspective for Clinical Trial Management Systems (CTMS) by End-Use - Percentage Breakdown of Value Sales for Large Pharma-Biotech Companies, CROs, Medical Device Manufacturers, Small & Mid-Sized Pharma-Biotech Companies and Other End-Uses for the Years 2014, 2024 & 2030
REST OF WORLD
TABLE 137: Rest of World Recent Past, Current & Future Analysis for Clinical Trial Management Systems (CTMS) by Deployment - Enterprise-Wide CTMS and On-Site CTMS - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
TABLE 138: Rest of World Historic Review for Clinical Trial Management Systems (CTMS) by Deployment - Enterprise-Wide CTMS and On-Site CTMS Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
TABLE 139: Rest of World 16-Year Perspective for Clinical Trial Management Systems (CTMS) by Deployment - Percentage Breakdown of Value Sales for Enterprise-Wide CTMS and On-Site CTMS for the Years 2014, 2024 & 2030
TABLE 140: Rest of World Recent Past, Current & Future Analysis for Clinical Trial Management Systems (CTMS) by Delivery mode - Web-Based (On-demand), Licensed Enterprise (On-Premise) and Cloud (SaaS) - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
TABLE 141: Rest of World Historic Review for Clinical Trial Management Systems (CTMS) by Delivery mode - Web-Based (On-demand), Licensed Enterprise (On-Premise) and Cloud (SaaS) Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
TABLE 142: Rest of World 16-Year Perspective for Clinical Trial Management Systems (CTMS) by Delivery mode - Percentage Breakdown of Value Sales for Web-Based (On-demand), Licensed Enterprise (On-Premise) and Cloud (SaaS) for the Years 2014, 2024 & 2030
TABLE 143: Rest of World Recent Past, Current & Future Analysis for Clinical Trial Management Systems (CTMS) by End-Use - Large Pharma-Biotech Companies, CROs, Medical Device Manufacturers, Small & Mid-Sized Pharma-Biotech Companies and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
TABLE 144: Rest of World Historic Review for Clinical Trial Management Systems (CTMS) by End-Use - Large Pharma-Biotech Companies, CROs, Medical Device Manufacturers, Small & Mid-Sized Pharma-Biotech Companies and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
TABLE 145: Rest of World 16-Year Perspective for Clinical Trial Management Systems (CTMS) by End-Use - Percentage Breakdown of Value Sales for Large Pharma-Biotech Companies, CROs, Medical Device Manufacturers, Small & Mid-Sized Pharma-Biotech Companies and Other End-Uses for the Years 2014, 2024 & 2030